Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$3 Mln
P/E Ratio
--
P/B Ratio
0.58
Industry P/E
--
Debt to Equity
--
ROE
-0.79 %
ROCE
462.45 %
Div. Yield
0 %
Book Value
5863682
EPS
13558458
CFO
$-45.08 Mln
EBITDA
$-72.24 Mln
Net Profit
$-53.11 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Synaptogenix Inc (SNPX)
| -31.56 | -11.38 | -32.72 | -47.57 | -24.05 | -- | -- |
|
BSE Sensex*
| 2.55 | 3.65 | 4.54 | 7.46 | 12.04 | 19.65 | 11.41 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
|
|---|---|---|---|---|
|
Synaptogenix Inc (SNPX)
| 1,149.53 | -76.55 | -86.37 | 41.83 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 38.55 | 10,593.45 | 21.84 | 23.13 | |
| 306.35 | 8,570.17 | 22.78 | 66.44 | |
| 27.82 | 10,589.59 | -- | -28.77 | |
| 107.24 | 10,559.67 | 32.44 | 14.16 |
Synaptogenix, Inc. operates as a biopharmaceutical company. The company is primarily focused on developing a product platform based upon Bryostatin-1, for the treatment of Alzheimer's disease (AD), which is in the clinical testing stage. It is also... evaluating potential therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis (MS), and Niemann-Pick Type C disease, which have undergone pre-clinical testing. The company was incorporated in 2012 and is headquartered in New York, New York. Address: 1185 Avenue of the Americas, New York, NY, United States, 10036 Read more
CEO & Director
Dr. Alan J. Tuchman M.D., MBA(FAAN)
CEO & Director
Dr. Alan J. Tuchman M.D., MBA(FAAN)
Headquarters
New York, NY
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Synaptogenix Inc (SNPX) stood at $ 17,733,779 Mln as on 31-Dec-24
The share price of Synaptogenix Inc (SNPX) is $2.38 (NASDAQ) as of 29-Apr-2025 16:00 EDT. Synaptogenix Inc (SNPX) has given a return of -24.05% in the last 3 years.
Synaptogenix Inc (SNPX) has a market capitalisation of $ 3 Mln as on 29-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Synaptogenix Inc (SNPX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Synaptogenix Inc (SNPX) and enter the required number of quantities and click on buy to purchase the shares of Synaptogenix Inc (SNPX).
Synaptogenix, Inc. operates as a biopharmaceutical company. The company is primarily focused on developing a product platform based upon Bryostatin-1, for the treatment of Alzheimer's disease (AD), which is in the clinical testing stage. It is also evaluating potential therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis (MS), and Niemann-Pick Type C disease, which have undergone pre-clinical testing. The company was incorporated in 2012 and is headquartered in New York, New York. Address: 1185 Avenue of the Americas, New York, NY, United States, 10036
The CEO & director of Dr. Alan J. Tuchman M.D., MBA(FAAN). is Synaptogenix Inc (SNPX), and CFO & Sr. VP is Dr. Alan J. Tuchman M.D., MBA(FAAN).
There is no promoter pledging in Synaptogenix Inc (SNPX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Synaptogenix Inc (SNPX) | Ratios |
|---|---|
|
Return on equity(%)
|
462.45
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Synaptogenix Inc (SNPX) was $0 Mln.
$-0.06
(
